Boryung plans to separate its prescription-drug sales and marketing operations into a wholly owned subsidiary, Boryung Pharma Solution, as part of its strategy to build a specialized commercial platform.
Celltrion has submitted a U.S. Phase 4 trial application to support the use of a higher 240 mg dose of Zymfentra, aiming to expand personalized dosing options and strengthen the drug's position in the U.S. market.
A South Korean study found that blood levels of complement proteins C1q and C3 may help predict amyloid reduction and ARIA risk in patients receiving lecanemab, though larger studies are needed.
Pentrym is testing whether targeting the tumor microenvironment alongside existing cancer drugs can overcome “false resistance” and improve treatment effectiveness.
